Citigroup Forecasts Strong Price Appreciation for Agilent Technologies (NYSE:A) Stock

Agilent Technologies (NYSE:A) had its price target lifted by equities research analysts at Citigroup from $185.00 to $190.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Citigroup’s price objective would indicate a potential upside of 20.85% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. HSBC cut their price target on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Royal Bank Of Canada lifted their target price on Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday. Wolfe Research reissued a “hold” rating on shares of Agilent Technologies in a research report on Tuesday, June 2nd. Robert W. Baird raised their price objective on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a report on Tuesday, May 26th. Finally, JPMorgan Chase & Co. lifted their price objective on Agilent Technologies from $180.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $170.33.

Agilent Technologies Trading Up 1.4%

A traded up $2.13 during trading on Thursday, hitting $157.22. The company’s stock had a trading volume of 1,992,931 shares, compared to its average volume of 2,232,849. The stock has a market cap of $44.40 billion, a PE ratio of 31.56, a PEG ratio of 2.73 and a beta of 1.25. The firm’s 50 day moving average price is $139.16 and its 200-day moving average price is $126.65. Agilent Technologies has a twelve month low of $108.35 and a twelve month high of $163.75. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period last year, the company earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, analysts expect that Agilent Technologies will post 6.05 earnings per share for the current year.

Institutional Trading of Agilent Technologies

A number of hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC lifted its position in shares of Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after purchasing an additional 270 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in Agilent Technologies by 15.9% during the 1st quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock worth $602,000 after buying an additional 769 shares during the last quarter. Geneos Wealth Management Inc. grew its position in shares of Agilent Technologies by 54.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock worth $70,000 after acquiring an additional 212 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Agilent Technologies by 16.5% in the 1st quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock valued at $625,000 after acquiring an additional 758 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Agilent Technologies during the 2nd quarter valued at approximately $273,000. Institutional investors and hedge funds own 87.41% of the company’s stock.

More Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.